ArticleCancer management and research2021
Clinical and Prognostic Implications of 1p/19q,
Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.Brain tumor pathology · 2023Pooled it
- A transformer-based multimodal deep learning model for preoperative prediction of Ki-67 expression level in glioma.BMC medical imaging · 2026Article
- Prognostic Importance of Histomolecular Subtyping of Central Nervous System Gliomas in Low and Middle-Income Countries.Brain tumor research and treatment · 2026Article
- Molecular features and tumor location interact to account for preoperative cognitive-emotional status in glioma.Frontiers in neurology · 2026Article
- The analysis of TOP2A as a potential target for predicting the prognosis of brain glioma in the TCGA database and in single-center study.Discover oncology · 2025Article
- Joint prediction of glioma molecular marker status based on GDI-PMNet.Journal of translational medicine · 2025Article
- The Prognostic Value of a Nomogram Model Based on Tumor Immune Markers and Clinical Factors for Adult Primary Glioma.Cancers · 2025Article
- Artificial Intelligent-Enhanced Metabolite Profiling for Intraoperative IDH1 Genotyping in Glioma Using an Orthogonally Responsive SERS Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Scinderin promotes glioma cell migration and invasionWorld journal of clinical oncology · 2024Article
- Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.NMR in biomedicine · 2022Review
- Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations.Frontiers in immunology · 2022Review
- DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.Frontiers in immunology · 2022Article
- Tumor treating fields plus temozolomide maintenance after radiochemotherapy in Chinese grade 4 gliomas: Efficacy and predictive biomarkers.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveGenetic alterations, including
methodsWe analyzed the prevalence and prognosis of these five alterations, as well as Ki-67 and p53 expression, in 103 primary grade II-IV gliomas via fluorescence qPCR, Sanger sequencing, fluorescence in situ hybridization, and immunohistochemistry.
resultsIn the 103 cases,
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.